Document Detail


Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: the effect of captopril and xamoterol.
MedLine Citation:
PMID:  8522409     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We measured left ventricular volume in 70 asymptomatic patients after first Q-wave anterior myocardial infarction in order to determine whether ventricular dilatation occurs and whether there is evidence for its attenuation or prevention by treatment with captopril or xamoterol--PRevention Of VEntricular Dilatation?: the PROVED? study. 77% of patients received thrombolytic treatment. Patients were randomised a mean of 11 days after infarction to receive either captopril 25 mg three times daily, xamoterol 200 mg twice daily or matching placebo. After 6 months of treatment, 6 patients from the placebo group (n = 24), 1 from the captopril group (n = 23) and 3 from the xamoterol group (n = 23) had been withdrawn from the study because of clinical complications. Left ventricular volume was measured using magnetic resonance imaging, before randomisation and after 6 months of treatment. Changes in left ventricular end-diastolic and end-systolic volume after 6 months of treatment were defined prospectively as the primary endpoints. Mean initial end-diastolic volume index was 85 (S.D. 19) ml/m2, mean end-systolic volume index was 45 (S.D. 18) ml/m2, and mean ejection fraction was 48 (S.D. 11)% for the whole group. There was no significant change in left ventricular volume index in the placebo or either treatment group after 6 months of treatment. Only minimal left ventricular dilatation was evident at 11 days. No further increase in left ventricular volume occurred after six months and there was no additional benefit from treatment with either captopril or xamoterol.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
K H Darasz; J Bayliss; S R Underwood; J Keegan; P A Poole-Wilson; G C Sutton
Related Documents :
11099679 - Systolic versus diastolic heart failure in community practice: clinical features, outco...
22056139 - Oncostatin m is a major mediator of cardiomyocyte dedifferentiation and remodeling.
3465579 - The use of digitalis in patients with chronic respiratory failure.
6479129 - Echocardiography in foals from birth to three months old.
2916689 - Direct diastolic ventricular interaction gain measured with sudden hemodynamic transients.
2965899 - Non-invasive measurement of stroke volume and left ventricular ejection fraction. radio...
24931179 - Epicardial ablation for prevention of ventricular fibrillation in a patient with brugad...
11374629 - Pancreatocolonic fistula due to severe acute pancreatitis: imaging findings.
15618069 - Association of lipoprotein-associated phospholipase a2 levels with coronary artery dise...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cardiology     Volume:  51     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  1995 Sep 
Date Detail:
Created Date:  1996-01-24     Completed Date:  1996-01-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  137-42     Citation Subset:  IM    
Affiliation:
National Heart and Lung Institute, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Captopril / therapeutic use*
Cardiac Volume / drug effects*
Cardiotonic Agents / therapeutic use*
Dilatation, Pathologic / etiology,  prevention & control
Double-Blind Method
Female
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Myocardial Infarction / drug therapy*
Placebos
Prospective Studies
Stroke Volume
Thrombolytic Therapy*
Ventricular Dysfunction, Left / etiology,  prevention & control
Ventricular Function, Left / drug effects*
Xamoterol / therapeutic use*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiotonic Agents; 0/Placebos; 62571-86-2/Captopril; 81801-12-9/Xamoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion.
Next Document:  Clinical and invasive 7-month follow-up of a patient with a synthetic coronary graft.